RE:RE:PDC deal I always tend to think that Complete Responses are hard to ignore in these late-stage patients so getting one early must help a lot. The technology is great, potentially it's cancer type, genetic mutation, cancer target agnostic given that it uses a biophysical feature of many (most?) tumours. You can imagine an almost infinite solid tumour cancer market once you've proved the big questions. It's interesting they are happy to pay the big cash after proving a few more things in Ph1 tends to make you think they are less interested in seeing one particular indication proven out and will take a risk on just some serious PoC data.
Could get into super-speculative, hopium mode and say this drug might benefit from working with a drug that reinforces the anoxic conditions of a tumour. Say something that inhibits vascular formation :)
palinc2000 wrote:
Your take on the science ...Lots of$$ for a delivery system still in Phase1